4,820 results match your criteria Anemia of Chronic Disease and Renal Failure


The Role of Plasmapheresis in Treating Lethal Cupric Sulfate Poisoning.

Authors:
Yu Du Yi Mou

Am J Med Sci 2018 Nov 29. Epub 2018 Nov 29.

Geroscience and Chronic Disease Department, The 8th Municipal People's Hospital, Chengdu, China. Electronic address:

The mortality rate of cupric sulfate is relatively high in contrast to that of other heavy metals. Cases of orally ingested cupric sulfate poisoning are very rare, with a reported half lethal dose of 10 g. Cupric sulfate poisoning leads to gastrointestinal corrosion, intravascular hemolysis, hemolytic anemia, methemoglobinemia and acute renal and hepatic impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2018.11.014DOI Listing
November 2018

Introduction to the Theme "New Therapeutic Targets".

Annu Rev Pharmacol Toxicol 2019 Jan;59:15-20

Biozentrum, University of Basel, CH-4056 Basel, Switzerland.

"New Therapeutic Targets" is the theme of articles in the Annual Review of Pharmacology and Toxicology, Volume 59. Reviews in this volume discuss targets for a variety of conditions in need of new therapies, including type 2 diabetes, heart failure with preserved ejection fraction, obesity, thyroid-associated ophthalmopathy, tinnitus, multiple sclerosis, Parkinson's disease and other neurodegenerative diseases, pain, depression, post-traumatic stress disorder, muscle wasting diseases, cancer, and anemia associated with chronic renal disease. Numerous articles in this volume focus on the identification, validation, and utility of novel therapeutic targets, in particular, ones that involve new or unexpected molecular entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pharmtox-101018-112717DOI Listing
January 2019

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature.

Front Pediatr 2018 18;6:398. Epub 2018 Dec 18.

Pediatric Nephrology Unit, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Anemia treatment in infants with advanced or chronic kidney disease (CKD) represents an important challenge to nephrologists. The use of darbepoetin alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human erythropoietin in older children and in adults with CKD. However, studies reporting the use of darbepoetin alfa in infants below 1 year of age are rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305342PMC
December 2018

Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Case-Control Study in a Primary Health Care Database.

Thromb Haemost 2019 Jan 31;119(1):66-76. Epub 2018 Dec 31.

Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.

Background:  Many patients on warfarin therapy often present with supratherapeutic international normalized ratio (INR) levels, resulting from the influence of several patient-specific factors, which have been associated with adverse outcomes.

Objective:  This article aims to identify risk factors for over-anticoagulation (INR levels ≥4) in a cohort of patients taking warfarin.

Methods:  A cohort of warfarin users aged 18 to 85 years from January 2005 to April 2013 was identified in The Health Improvement Network U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1676519DOI Listing
January 2019

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Am J Kidney Dis 2018 Dec 19. Epub 2018 Dec 19.

Harvard Medical School, Boston, MA; Cardiology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA.

Rationale & Objective: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes.

Study Design: Post hoc analysis of a randomized controlled trial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02726386183108
Publisher Site
http://dx.doi.org/10.1053/j.ajkd.2018.10.006DOI Listing
December 2018
5 Reads
5.900 Impact Factor

Vitamin E deficiency in South Asian population and the therapeutic use of alpha-tocopherol (Vitamin E) for correction of anemia.

Pak J Med Sci 2018 Nov-Dec;34(6):1571-1575

Prof. Dr. Mohammad Perwaiz Iqbal, PhD. Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan.

Mild to moderate vitamin E deficiency because of inadequate consumption of vitamin E-rich foods and intestinal fat malabsorption is common in growing children, women of reproductive age and elderly South Asian population. Severe vitamin E deficiency may lead to peripheral and motor neurodegenerative diseases (e.g ataxia and motor skeletal myopathy), impaired immune response and free radical-induced hemolytic anemias. Read More

View Article

Download full-text PDF

Source
http://pjms.com.pk/index.php/pjms/article/view/15880
Publisher Site
http://dx.doi.org/10.12669/pjms.346.15880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290196PMC
December 2018
5 Reads

Effects of Molidustat in the Treatment of Anemia in CKD.

Clin J Am Soc Nephrol 2019 Jan 17;14(1):28-39. Epub 2018 Dec 17.

Departments of Research and Development, and Pharmaceuticals, Bayer AG, Wuppertal, Germany.

Background And Objectives: The efficacy and safety of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, have been evaluated in three 16-week, phase 2b studies in patients with CKD and anemia who are not on dialysis (DaIly orAL treatment increasing endOGenoUs Erythropoietin [DIALOGUE] 1 and 2) and in those who are on dialysis (DIALOGUE 4).

Design, Setting, Participants, & Measurements: DIALOGUE 1 was a placebo-controlled, fixed-dose trial (25, 50, and 75 mg once daily; 25 and 50 mg twice daily). DIALOGUE 2 and 4 were open-label, variable-dose trials, in which treatment was switched from darbepoetin (DIAGLOGUE 2) or epoetin (DIALOGUE 4) to molidustat or continued with the original agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.02510218DOI Listing
January 2019

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Lancet HIV 2018 Dec 13. Epub 2018 Dec 13.

Department of HIV Clinical Research, Gilead Sciences, Foster City, CA, USA. Electronic address:

Background: Current treatment for HIV-infected individuals with renal failure on haemodialysis frequently requires complex regimens with multiple pills. A daily single-tablet regimen of coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is approved in Europe, the USA, and in other regions for use in HIV-1-infected individuals with mild-to-moderate chronic kidney disease (creatinine clearance 30-69 mL/min). We aimed to assess the safety, efficacy, and pharmacokinetics of this regimen in HIV-infected adults with end-stage renal disease on chronic haemodialysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3018(18)30296-0DOI Listing
December 2018
2 Reads

Snap shot view on anaemia in Chronic Kidney Disease of uncertain aetiology.

Nephrology (Carlton) 2018 Dec 7. Epub 2018 Dec 7.

Transplant and Dialysis Unit, Teaching Hospital, Kandy, Sri Lanka.

Aim: Anaemia is a well-known complication of Chronic Kidney Disease (CKD) but there are no published studies on the pattern of anaemia in Chronic Kidney Disease of uncertain aetiology (CKDu). This study aims to find out the prevalence, causes and associations of anaemia in CKDu to identify any unique features which are different from already described Anaemia in CKD.

Method: All (119) biopsy-confirmed CKDu patients in two endemic clinics (Girandurukotte and Wilgamuwa) were selected as cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/nep.13545DOI Listing
December 2018
2 Reads
1.864 Impact Factor

Dental Care for Patients with End-Stage Renal Disease and Undergoing Hemodialysis.

Int J Dent 2018 13;2018:9610892. Epub 2018 Nov 13.

Unit of Periodontology and Dental Hygiene, School of Dental Sciences, Department of Medical, Surgical and Health Sciences, University of Trieste, Italy.

Chronic renal failure is a progressive disease characterized by a gradual destruction of nephrons and a consequent reduction of kidney function. End-stage renal disease (ESRD) necessitates renal replacement therapy as peritoneal dialysis, hemodialysis, or transplantation. Patients affected by ESRD or in hemodialysis are at risk for developing a number of comorbidities including hypertension, anemia, risk of bleeding, susceptibility to infection, medication side effects, and oral manifestations associated with the disease itself and with hemodialysis treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9610892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258100PMC
November 2018
1 Read

Renal Functions and Prognosis Stratification in Chronic Heart Failure Patients and the Importance of Neutrophil Gelatinase-Associated Lipocalin.

Kidney Blood Press Res 2018 7;43(6):1865-1877. Epub 2018 Dec 7.

Department of Internal Cardiology Medicine, Faculty Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Background/aims: The rate of incidence and prevalence of acute kidney injury is increasing due to an increased number of patients with heart failure. Therefore it is very pertinent to early detect the level of renal injuries and to make necessary heart failure predictions. Thus the aim of this study is to determine renal functions and prognosis stratification in chronic heart failure patients and importance of Neutrophil Gelatinase-Associated Lipocalin (NGAL), an early diagnostic marker of acute kidney injury, as well as stratification of cardiovascular risk in heart failure patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495819DOI Listing
December 2018
2 Reads

Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes.

Diabetes Metab Syndr Obes 2018 15;11:707-716. Epub 2018 Nov 15.

Department of Epidemiology, School of Public Health, West Virginia University, Morgantown, WV, USA,

Background: Anemia often complicates chronic kidney disease (CKD), leading to insufficient tissue oxygenation and hypoxic injury, the factor thought to underlie progression from CKD to renal failure. Perfluorocarbons are potent oxygen transporters used in organ preservation and synthetic blood development. Data are scarce on their relationship with kidney function, especially in diabetes where anemia and hypoxia are more prevalent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DMSO.S173809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244585PMC
November 2018
1 Read

Patients with Atrial Fibrillation and Chronic Kidney Disease More Often Undergo Angioplasty of Left Main Coronary Artery - a 867 Patient Study.

Kidney Blood Press Res 2018 30;43(6):1796-1805. Epub 2018 Nov 30.

Cardiology Department, Ioannina University Hospital, Ioannina, Greece.

Background/aims: Several studies have implicated atrial fibrillation (AF) as a contributing factor in chronic kidney disease (CKD) and cardiovascular events. The prevalence of coronary artery disease (CAD) in patients with AF varies substantially from 17% to 46.5%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495637DOI Listing
November 2018
1 Read

Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: Presentations, causes and treatment strategies.

Authors:
Sherifa A Hamed

Expert Rev Clin Pharmacol 2018 Dec 2. Epub 2018 Dec 2.

a Department of Neurology and Psychiatry , Assiut University Hospital , Assiut , Egypt.

Introduction: Uremic syndrome of chronic kidney disease (CKD) is a term used to describe clinical, metabolic and hormonal abnormalities associated with progressive kidney failure. It is a rapidly growing public health problem worldwide. Nervous system complications occur in every patient with uremic syndrome of CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1555468DOI Listing
December 2018
1 Read

Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort.

Am J Kidney Dis 2018 Oct 10. Epub 2018 Oct 10.

Division of Nephrology, Department of Medicine, University of California, San Francisco, CA; Division of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA; Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA.

Rationale & Objective: Acute kidney injury (AKI) has numerous sequelae. Repeated episodes of AKI may be an important determinant of adverse outcomes, including chronic kidney disease and death. In a population-based cohort study, we sought to determine the incidence of and predictors for recurrent AKI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2018.08.008DOI Listing
October 2018

[Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia].

Nephrol Ther 2018 Nov;14(6S):6S17-6S25

Service de néphrologie, hôpital Necker-Enfants malades, 149, rue de Sèvres 75015 Paris, France. Electronic address:

Metabolic complications of chronic kidney disease (CKD) are frequent; the aims of this review are to present a 2018 update for hyperkalemia, hyperphosphatemia and anemia. Hyperkalemia is defined by a plasma level above 5.0 mmol/L, after ruling out pre-analytical problems such as hemolysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1769-7255(18)30647-3DOI Listing
November 2018
1 Read

Iron status in dogs with myxomatous mitral valve disease.

Pol J Vet Sci 2018 Sep;21(3):507-515

Department of Veterinary Medicine (DIMEVET), University of Milan, via Celoria 10, 20133 Milan, Italy.

In humans, iron deficiency represents a relevant occurrence in heart failure (HF), with or without anaemia, and is associated with the worst outcome. Moreover, chronic kidney disease (CKD) is a well-known comorbidity of HF and is strongly associated with the risk of developing anaemia. The most common cause of HF in dogs is myxomatous mitral valve disease (MMVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24425/122625DOI Listing
September 2018
14 Reads

Meta-analysis of risk and protective factors for gastrointestinal bleeding after percutaneous coronary intervention.

Int J Nurs Pract 2018 Nov 19:e12707. Epub 2018 Nov 19.

School of Health Sciences of Wuhan University, Wuhan, China.

Aim: To quantitatively analyse factors related to gastrointestinal bleeding after percutaneous coronary intervention and provide evidence for the prevention of gastrointestinal bleeding.

Data Sources And Review Methods: Cochrane Library, Pubmed, Embase, and Ovid databases were searched from inception to 31 May 2018; case-control and cohort studies published in English were included. The methodological quality of each study was assessed by two independent reviewers using the Newcastle-Ottawa Scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijn.12707DOI Listing
November 2018
6 Reads

Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women.

Heart Fail Clin 2019 Jan 24;15(1):1-8. Epub 2018 Oct 24.

The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA.

Sex specific differences exist in the impact of risk factors for the development of heart failure (HF). Addressing these differences can have an impact on prevention of HF. This article reviews sex-specific risk factors associated with development of HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.001DOI Listing
January 2019
13 Reads

[Cardiac complications of sickle cell disease in children].

Rev Med Liege 2018 Nov;73(11):550-556

Service de Pédiatrie, CHU de Liège, Belgique.

Sickle cell disease (SCD) is a genetic disorder due to an abnormal gene coding for the chain ? of the hemoglobin. The main clinical manifestations related to the major forms of SCD (SS-, SC-, and S-thalassemia) are chronic hemolysis, susceptibility to infections and vasoconstrictive crisis causing micro-emboli and/or infarction responsible for acute or chronic organ lesions. The latest are enhanced by tissue iron overload due to repeated blood transfusions. Read More

View Article

Download full-text PDF

Source
November 2018
12 Reads

Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.

Medicine (Baltimore) 2018 Nov;97(44):e13103

Rationale: The abnormal cell types in chronic myeloid leukemia (CML) and monoclonal gammopathy of uncertain (MGUS) are quite different, being myeloid and plasma cells, respectively. The coexistence of CML and MGUS is an uncommon event, which is seldom reported in literature.

Patient Concerns: A 52-year-old female was diagnosed with CML in April 2001. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221681PMC
November 2018
2 Reads

Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia.

Pharmaceuticals (Basel) 2018 Oct 11;11(4). Epub 2018 Oct 11.

Hull York Medical School & Department of Renal Medicine, Hull and East Yorkshire NHS Hospital Trust, Hull HU3 2JZ, UK.

Patients with chronic kidney disease (CKD) have significant cardiovascular morbidity and mortality as a result of risk factors such as left ventricular hypertrophy (LVH), oxidative stress, and inflammation. The presence of anaemia in CKD further increases the risk of LVH and oxidative stress, thereby magnifying the deleterious consequence in uraemic cardiomyopathy (UCM), and aggravating progression to failure and increasing the risk of sudden cardiac death. This short review highlights the specific cardio-renal oxidative stress in CKD and provides an understanding of the pathophysiology and impact of uraemic toxins, inflammation, and anaemia on oxidative stress. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1424-8247/11/4/103
Publisher Site
http://dx.doi.org/10.3390/ph11040103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316624PMC
October 2018
2 Reads

Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study.

J Korean Med Sci 2018 Oct 12;33(42):e264. Epub 2018 Sep 12.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Background: Hepatitis B virus (HBV) infection leads to hepatic and extrahepatic manifestations including chronic kidney disease (CKD). However, the association between HBV and CKD is not clear. This study investigated the association between chronic HBV infection and CKD in a nationwide multicenter study. Read More

View Article

Download full-text PDF

Source
https://jkms.org/DOIx.php?id=10.3346/jkms.2018.33.e264
Publisher Site
http://dx.doi.org/10.3346/jkms.2018.33.e264DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179986PMC
October 2018
7 Reads

Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.

Am J Nephrol 2018 10;48(4):260-268. Epub 2018 Oct 10.

Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.

Background: Intravenous (IV) iron supplementation is a standard maintenance treatment for hemodialysis (HD) patients, but the optimum dosing regimen is unknown.

Methods: PIVOTAL (Proactive IV irOn Therapy in hemodiALysis patients) is a multicenter, open-label, blinded endpoint, randomized controlled (PROBE) trial. Incident HD adults with a serum ferritin < 400 µg/L and transferrin saturation (TSAT) levels < 30% receiving erythropoiesis-stimulating agents (ESA) were eligible. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/493551
Publisher Site
http://dx.doi.org/10.1159/000493551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262676PMC
October 2018
17 Reads

Acupuncture Application in Chronic Kidney Disease and its Potential Mechanisms.

Am J Chin Med 2018 ;46(6):1169-1185

* Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P. R. China.

Chronic kidney disease (CKD) is an increasing major public health problem worldwide. The number of CKD patients on hemodialysis is growing rapidly as well. Acupuncture technique is one of the traditional Chinese medicine methods and has been used in a variety of diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1142/S0192415X18500611DOI Listing
December 2018
1 Read

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis.

J Clin Med 2018 Sep 29;7(10). Epub 2018 Sep 29.

Center for Evidence-Based Medicine, Department of Education, Taipei Medical University Hospital, Taipei 110, Taiwan.

The effectiveness and safety of direct-acting antiviral agents (DAAs) in hepatitis C virus (HCV) patients with renal insufficiency remain controversial. Therefore, this network meta-analysis aims to assess effectiveness and safety of DAAs in populations with different renal function. The pooled data were obtained from Cochrane Library, EMBASE, PubMed, and Web of Science. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm7100314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210726PMC
September 2018
7 Reads

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease.

Drug Des Devel Ther 2018 18;12:3003-3011. Epub 2018 Sep 18.

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China,

Introduction: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.

Methods: Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence of adverse events (AEs) were extracted and pooled using Review Manager Version 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S175887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151102PMC
December 2018
1 Read

Castleman disease mimicking systemic lupus erythematosus: A case report.

Medicine (Baltimore) 2018 Sep;97(38):e12291

Key Laboratory of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology.

Rationale: Castleman disease (CD) is a nonclonal lymphoproliferative disorder sometimes manifested systemic inflammatory symptoms. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized with multi-system involvement as well as broad spectrum of serum autoantibodies. When these two conditions happened to have similar clinical spectrum features, the confusion with each other occurred. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160051PMC
September 2018
2 Reads
5.720 Impact Factor

Ochronosis Presenting as Methemoglobinemia.

J Forensic Sci 2018 Sep 19. Epub 2018 Sep 19.

Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.

Ochronosis is the blue-gray discoloration of collagen-containing tissues due to homogentisic acid (HGA) deposition, secondary to endogenous alkaptonuria or exogenous enzyme inhibition. In renal disease, accumulation of HGA in serum can cause methemoglobinemia. A 60-year-old woman with renal disease and anemia presented with 3 days of weakness and months of gray skin discoloration. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1556-4029.13907
Publisher Site
http://dx.doi.org/10.1111/1556-4029.13907DOI Listing
September 2018
16 Reads

Application of a Nanotechnology-Based, Point-of-Care Diagnostic Device in Diabetic Kidney Disease.

Kidney Int Rep 2018 Sep 2;3(5):1110-1118. Epub 2018 Jun 2.

PathShodh Healthcare Pvt. Ltd., Bangalore, India.

Introduction: Early detection of diabetes mellitus (DM) and diabetic kidney disease (DKD) is important for preventing end-stage renal failure and reducing cardiovascular complications. Availability of a validated point-of-care (PoC) device that can measure various DKD markers would be useful in this respect, especially in resource-poor parts of the world.

Methods: We validated a novel nanotechnology-based multianalyte PoC device (minimally invasive and does not require trained medical personnel) against laboratory gold standard tests for the detection of 5 biomarkers related to management of DM and DKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ekir.2018.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127407PMC
September 2018
2 Reads

Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients.

Ann Transplant 2018 Sep 7;23:631-638. Epub 2018 Sep 7.

Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, OH, USA.

BACKGROUND Atypical hemolytic uremic syndrome (aHUS), a rare thrombotic microangiopathy, is characterized by hemolytic anemia, thrombocytopenia, and acute renal failure. Caused by genetic mutations in the alternative complement cascade, aHUS often will culminate in end-stage renal disease and occasionally death. Renal transplantation in aHUS patients has been contraindicated in the past due to the recurrence risk, with certain immunosuppressive regimens being commonly attributed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AOT.909781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248048PMC
September 2018
3 Reads

Trends and Patient Characteristics Associated with Tobacco Pharmacotherapy Dispensed in the Veterans Health Administration.

Nicotine Tob Res 2018 Sep;20(10):1173-1181

VA Center for Clinical Management and Research, Department of Veterans Affairs Healthcare System, Ann Arbor, MI.

Introduction: There is evidence suggesting that certain subgroups of people who use tobacco do not receive tobacco pharmacology as consistently as others.

Methods: This retrospective, cohort study examined the trend in the use of cessation pharmacotherapy from 2004 to 2013 using Veterans Health Administration (VHA) administrative data. Among Veterans who used tobacco in the fiscal year (FY) 2011 and had not received pharmacotherapy in the prior year, multivariable Cox regression was used to assess the independent associations between patient clinical and demographic characteristics and pharmacotherapy initiation in the 6-months follow-up period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ntr/ntx229DOI Listing
September 2018
2 Reads
3.300 Impact Factor

Upper Gastrointestinal Bleeding of Unusual Causation.

Dig Dis Sci 2018 10;63(10):2541-2546

Division of Gastroenterology and Hepatology, Department of Medicine, University of New Mexico School of Medicine, MSC 10-5550, 87131, Albuquerque, NM, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-018-5260-8DOI Listing
October 2018
1 Read

Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry.

J Cardiovasc Electrophysiol 2018 Nov 25;29(11):1540-1547. Epub 2018 Sep 25.

Electrophysiology and Pacing Unit, Soroka University Medical Center, Beer Sheva, Affiliated with Ben-Gurion University of the Negev, Beer Sheva, Israel.

Introduction: Life expectancy of less than 1 year is usually a contraindication for implantable cardioverter defibrillator (ICD) implantation. The aim was to identify patients at risk of death during the first year after implantation.

Methods And Results: Data were derived from a prospective Israeli ICD Registry. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jce.13725
Publisher Site
http://dx.doi.org/10.1111/jce.13725DOI Listing
November 2018
29 Reads

Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.

Clin Res Hepatol Gastroenterol 2018 Aug 27. Epub 2018 Aug 27.

Tropical Medicine and Gastroenterology Department, Hepatology Division, Faculty of Medicine, Sohag university, Sohag, Egypt.

Background: Till now, pooled data about the safety and efficacy of different direct-acting antiviral (DAAs) regimens in different renal situations are still under evaluation.

Aim: To evaluate a real-life experience of the efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) in patients with end-stage kidney disease (ESKD).

Patients And Methods: Between January 2017 and January 2018, an open-label multicenter prospective study was designed to enroll all consecutive patients with proven CHC genotype 4 infections and concomitant ESKD based on estimated glomerular filtration rate (eGFR) with (HD group) or without hemodialysis (non-HD group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2018.08.003DOI Listing
August 2018
5 Reads

Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.

Nutrients 2018 Aug 27;10(9). Epub 2018 Aug 27.

Department of Internal Medicine, Public Central Hospital of Matto Ishikawa, 3-8 Kuramitsu, Hakusan, Ishikawa 924-8588, Japan.

Iron deficiency anemia (IDA) is a major problem in chronic kidney disease (CKD), causing increased mortality. Ferritin stores iron, representing iron status. Hepcidin binds to ferroportin, thereby inhibiting iron absorption/efflux. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu10091173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163440PMC
August 2018
6 Reads

Erythropoietin preparation drastically improved activities of daily living in a patient with severe dementia.

Psychiatry Clin Neurosci 2018 11 8;72(11):849. Epub 2018 Oct 8.

Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcn.12777DOI Listing
November 2018
1 Read

The characteristics and prescription patterns of Chinese herbal medicine in clinical practice for the treatment of anemia.

Taiwan J Obstet Gynecol 2018 Aug;57(4):570-577

Department of Chinese Medicine, China Medical University Hospital, Taichung, Taiwan; School of Chinese Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung 40447, Taiwan; Cancer Research Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:

Objective: Chinese herbal medicine (CHM) is frequently applied to patients to improve the symptoms and signs associated with anemia. The aim of this study is to use the claims data from the National Health Insurance Research Database (NHIRD) in Taiwan to analyze CHM prescription patterns and to identify the frequency and combinations of CHM commonly used to treat anemia.

Materials And Methods: A total of 41,028 patients were diagnosed with anemia in Taiwan within the defined study period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tjog.2018.06.030DOI Listing
August 2018
16 Reads

[A special form of pancytopenia].

Pan Afr Med J 2018 9;29:209. Epub 2018 Apr 9.

Service d'Anatomie Pathologique, Hôpital Militaire, d'Instruction Mohamed V, Rabat, Maroc.

Primary hyperoxaluria is a rare disease whose incidence is estimated at less than 1 cases/million inhabitants/year. This is a congenital abnormality of hepatic metabolism leading to an endogenous overproduction of oxalate with excess urinary excretion. We report the case of a 43-year-old patient, was followed to end-stage renal disease hemodialysis, consulting for anemic syndrome with mucocutaneous pallor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11604/pamj.2018.29.209.14055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080970PMC
August 2018
2 Reads

A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia.

Crit Rev Oncol Hematol 2018 Sep 19;129:79-90. Epub 2018 Jun 19.

Indiana University Health, Indianapolis, IN, USA.

Erythropoiesis-stimulating agents (ESAs) are man-made forms of erythropoietin used in the treatment of anemia. This quick-scoping review of systematic literature reviews (SLRs) was conducted to define the clinical, economic, and health-related quality of life (HRQoL) outcomes for short-acting and long-acting ESAs in patients with chronic kidney disease-induced anemia (CKD-IA) and patients with chemotherapy-induced anemia (CIA). Embase, Medline, and the Cochrane Database of Systematic Reviews were searched from their establishment until October 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.06.010DOI Listing
September 2018
4 Reads

Adult Henolch-Schonlein purpura: multiorgan failure in the setting of a purpuric rash.

BMJ Case Rep 2018 Aug 9;2018. Epub 2018 Aug 9.

Internal Medicine, University of Tennessee at Chattanooga, College of Health Education and Professional Studies, Chattanooga, Tennessee, USA.

We report a 66-year-old man with a history of congestive heart failure, atrial fibrillation on warfarin therapy and chronic kidney disease that presented with acute dyspnoea. He had multiple palpable purpuric lesions on his bilateral lower extremities. Laboratory findings supported acute anaemia with no obvious bleeding source, supratherapeutic international normalised ratio and acute on chronic kidney injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-224816DOI Listing
August 2018
3 Reads

Alkaline Diet: a Novel Nutritional Strategy in Chronic Kidney Disease?

Iran J Kidney Dis 2018 07;12(4):204-208

Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, Iran.

Chronic kidney disease is defined as a glomerular filtration rate lower than 60 mL/min/1.73 m2, which is regarded as a public health priority and part of the growing burden of noncommunicable diseases. Reduced kidney function is concomitant with high levels of inflammatory factors, abnormal lipid profile, and anemia, as well as bone abnormalities, calcium deposition outside the bones, endothelial dysfunction, and cardiomyopathy. Read More

View Article

Download full-text PDF

Source
July 2018
6 Reads

Kidney Transplant Recipients With Rheumatic Diseases: Epidemiological Data From the Polish Transplant Registries 1998-2015.

Transplant Proc 2018 Jul - Aug;50(6):1654-1657. Epub 2018 Mar 28.

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, Warsaw, Poland; Department of Bioinformatics, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.

Chronic kidney disease (CKD) is a common complication of rheumatic disorders. We analyzed the incidence of different rheumatic conditions as a primary diagnosis of end-stage renal disease (ESRD) in kidney transplant recipients in Poland. Data were received from the national waiting list for organ transplantation (Poltransplant) registries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.03.122DOI Listing
October 2018
3 Reads

Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.

Clin Nephrol 2018 Oct;90(4):276-285

Background: Standard protocol-based approaches to erythropoiesis stimulating agent (ESA) dosing in anemia management of end-stage renal disease (ESRD) fail to address the inter-individual variability in patient's response to ESA. We conducted a single-center quality improvement project to investigate the long-term performance of a computer-designed dosing system.

Materials And Methods: The study was a retrospective case-control study with long-term follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CN109499DOI Listing
October 2018

Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats.

J Ethnopharmacol 2018 Oct 23;225:327-335. Epub 2018 Jul 23.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, PR China. Electronic address:

Ethnopharmacological Relevance: Baoyuan decoction (BYD), a traditional Chinese medicine (TCM) formula, is composed of four herbs and widely used with western drugs to treat coronary heart disease, aplastic anemia and chronic renal failure in clinic. However, no study of the effect of BYD on the cytochrome P450 (CYP) activities has been reported.

Aim Of The Study: The purpose of the present study was to evaluate the potential influences of BYD on the activities of seven CYP isozymes (CYP1A2, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4) in rats. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03788741183111
Publisher Site
http://dx.doi.org/10.1016/j.jep.2018.07.023DOI Listing
October 2018
14 Reads
3.000 Impact Factor

Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review.

Ther Apher Dial 2018 Oct 18;22(5):444-456. Epub 2018 Jul 18.

Health Economics and Outcomes Research, Creativ-Ceutical, Paris, France.

Anemia is a common complication for patients with chronic kidney disease (CKD) and is associated with cardiovascular comorbidities and reduced quality of life. The incidence of anemia increases as kidney function declines and affects approximately 32% of Japanese patients with stage 3-5 CKD. This review examined the current literature on anemia in CKD patients in Japan to provide an overview of the burden of anemia in CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1744-9987.12712DOI Listing
October 2018
15 Reads

Comparison of four eGFR equations in assessing complications associated with chronic loss of kidney function: A cross-sectional study in a Chinese population
.

Clin Nephrol 2018 Oct;90(4):246-254

There are various equations for estimating glomerular filtration rate (eGFR), mainly including abbreviated Modification of Diet in Renal Disease Study Equations (aMDRD), c-aMDRD for the Chinese population, Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI 2009) and Creatinine-Cystatin C equation (CKD-EPI 2012). Currently, it is unclear which eGFR equation more realistically predicts and reflects the development of complications closely associated with chronic loss of kidney function. Our study selected a total of 1,012 nondialysis patients at stages 2 through 4 chronic kidney disease (CKD) to assess these complications using eGFR calculated by these four equations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5414/CN109353DOI Listing
October 2018
8 Reads

Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study.

Nephron 2018 17;140(1):39-47. Epub 2018 Jul 17.

IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.

Background: Lack of adequate management of chronic kidney disease (CKD) often results in delayed diagnosis and inadequate treatment. This study assessed the clinical management and outcome of stages 1-5 CKD patients.

Methods: Patients were prospectively followed for 3 years in 25 nephrology centers across Italy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000490769DOI Listing
July 2018
7 Reads

[Atypical hemolytic uremic syndrome. Report of two cases treated with Eculizumab].

Rev Med Chil 2018 Feb;146(2):254-259

Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Hemolytic uremic syndrome (HUS) is a type of thrombotic microangiopathy where organic damage predominates in the kidney. Atypical HUS (aHUS) is a rare disease that affects young adults and causes terminal chronic renal failure ending in dialysis, in most cases. It also recurs after kidney transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/s0034-98872018000200254DOI Listing
February 2018
5 Reads